Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

Table 5

Virologic and immunologic outcomes at Week 48.

Week 48 outcomes	Atazanavir/ritonavir 300/100 mg qd + one NRTI + etravirine; 200 mg bid ()	Atazanavir/ritonavir 400/100 mg qd + one NRTI + etravirine 200 mg bid ()	All patients; ()
ITT, NC = F
^*VL < 50 copies/mL, (%)	11 (50.0)	10 (45.5)	21 (47.7)
VL < 400 copies/mL, (%)	11 (50.0)	13 (59.1)	24 (54.5)
^†, mean (SE) change from prebaseline; (Week −2)	−1.4 (0.24)	−1.4 (0.29)	−1.4 (0.18)
^‡Increase from prebaseline in absolute CD4^+ count,; cells/mm^3 (mean (SE)) (NC = F)	105 (31.1)	132 (32.6)	118 (22.3)
Snapshot
VL < 50 copies/mL [ (%)]	11 (50.0)	10 (45.5)	21 (47.7)

, logistic regression; ^† = 0.845, ANCOVA; and ^‡ = 0.714, ANCOVA for comparison between the two treatment groups, corrected for baseline VL and baseline CD4⁺ count respectively.
ITT: intent-to-treat; : number of patients per treatment group; (%): number (proportion) of patients with observations; NC = F: noncompleter equals failure (missing values after discontinuation imputed with change = 0; last observation was carried forward otherwise); NRTI: nucleoside reverse transcriptase inhibitor; SE: standard error; VL: viral load.